Oct 2026· Journal of Visualized Experiments· Vol 236· 0 citations
Medicine
TL;DR
These findings identify eight MP-related hub genes as candidate prognostic biomarkers and provide a risk model with acceptable predictive performance, offering insights into the immune-metabolic interplay in MM and suggesting potential avenues for personalized therapeutic strategies.
Abstract
Multiple myeloma (MM) is an incurable hematologic neoplasm with heterogeneous prognosis. Within the bone marrow microenvironment, macrophage polarization (MP) contributes to immune remodeling and may influence disease progression, yet MP-related prognostic biomarkers remain insufficiently characterized. In this study, we integrated transcriptomic data from UCSC Xena (n = 844) and GSE4581 (n = 414) to identify differentially expressed genes between immune-hot and immune-cold MM samples stratified by single-sample gene set enrichment analysis (ssGSEA)-derived immune scores. Weighted gene co-expression network analysis (WGCNA) and intersection with published MP-related genes yielded candidate genes, which were further refined using univariate Cox regression combined with least absolute shrinkage and selection operator (LASSO), eXtreme gradient boosting (XGBoost) and support vector machine recursive feature elimination (SVM-RFE) machine learning algorithms to construct a prognostic model. An eight-gene signature (LGALS3, IL2RG, ADAM8, MERTK, ACSS1, ARSK, CBX6 and SOCS3) was established, demonstrating acceptable discriminatory ability for 1-, 2-, and 3-year overall survival (AUC 0.666-0.736 in training cohort). Risk groups differed significantly in immune infiltration patterns, predicted drug sensitivity, and survival outcomes. A predicted competing endogenous RNA (ceRNA) network centered on MERTK and SOCS3 was also constructed. These findings identify eight MP-related hub genes as candidate prognostic biomarkers and provide a risk model with acceptable predictive performance, offering insights into the immune-metabolic interplay in MM and suggesting potential avenues for personalized therapeutic strategies.
Novel molecular markers and immune regulatory pathways are uncovered, providing insight into MM prognosis and possible therapeutic strategies, using integrated bioinformatics, machine learning, and experimental approaches.
Wen-Jing Li, Li Li, Yu Sun et al.· American journal of translat...· 0 citations
BACKGROUND
Thyroid carcinoma (THCA) represents the most prevalent malignancy of the endocrine system. Although the majority of patients exhibit favorable clinical outcomes, a subset still faces significant clinical challenges, including distant metastasis, recurrence, and poor response to therapeutic interventions, all...
Liang Chen, Chao-Hon Fu, Yang Chen et al.· Advances in Clinical and Exp...· 0 citations
Background This study aimed to investigate the associations of senescence-associated secretory phenotype (SASP)-related genes with the tumor immune microenvironment (TIME) and clinical outcomes in lung adenocarcinoma (LUAD) and to develop and evaluate a prognostic signature for risk stratification and exploratory treat...
The risk model based on FN1 and TIMP1 are identified as pivotal MacPCD-related prognostic genes in GBM, offering a reliable tool for clinical prognosis and paving the way for personalized immunotherapy strategies.
The PRS captures prognostic heterogeneity and distinct immune microenvironment features in DLBCL and may provide a useful tool for risk stratification, and CEACAM3 may serve as a potential biomarker and therapeutic target in DLBCL.
Jie Zhang, Xiao-Bing Miao, Hao Yang et al.· Frontiers in Immunology· 0 citations
High-grade (FIGO Grade 3) uterine corpus endometrial carcinoma (UCEC) is an aggressive malignancy with limited therapeutic options and a poor prognosis. While ferroptosis is implicated in various cancers, its specific role within the tumor immune microenvironment of high-grade UCEC remains unclear.
We anal...
Yu Chen, Xi-Die Li, Yi-Fan Li et al.· World Journal of Surgical On...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.